Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Depreciation & Amortization (CF) (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 6.99% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, down 1.52% year-over-year, with the annual reading at $13.1 million for FY2025, 1.53% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $3.6 million at Century Therapeutics, up from $3.1 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $3.6 million in Q4 2023, with the low at $1.2 million in Q1 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $3.0 million, with a median of $3.2 million recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) surged 150.69% in 2023, then decreased 7.54% in 2025.
  • Over 4 years, Depreciation & Amortization (CF) stood at $2.8 million in 2022, then grew by 25.16% to $3.6 million in 2023, then fell by 6.59% to $3.3 million in 2024, then rose by 6.99% to $3.6 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $3.6 million, $3.1 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.